ROIV Roivant Sciences Ltd.
Nasdaq · SEC CIK 1635088 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $897.02M 47 sales by 12 insiders
- Filings on record
- 427 since 2021-10-22, latest 2026-09-22 21:00
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| MANCHESTER KEITH S | Dir | — | $154.47M |
| Gold Daniel Allen | Dir | — | $147.38M |
| QVT Financial LP | Dir by Deputization | — | $147.38M |
| Sukhatme Mayukh | Pres, CIO, Dir | — | $109.13M |
| Ramaswamy Vivek | 10% | — | $105.88M |
| Venker Eric | Pres, Immunovant CEO | — | $89.77M |
| Torti Frank | Pres, Vant COB | — | $82.04M |
| Gline Matthew | CEO, Dir | — | $46.17M |
| Pulik Richard | CFO | — | $9.12M |
| Fitzgerald Meghan | Dir | — | $3.27M |
Transactions 563
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-29 | 2025-12-23 | ROIV | Pulik Richard | CFO | M - OptEx | $3.85 | +260.0K | 646.1K | +67% | +$1.00M |
| 2025-12-29 | 2025-12-24 | ROIV | Torti Frank | Pres, Vant COB | J - Other | $22.47 | -64.9K | 13.85M | -0.5% | -$1.46M | |
| 2025-12-29 | 2025-12-24 | ROIV | Torti Frank | Pres, Vant COB | G - Gift | $0.00 | -110.5K | 13.74M | -0.8% | $0 | |
| 2025-12-29 | 2025-12-23 | ROIV | Torti Frank | Pres, Vant COB | A - Grant | $22.45 | +175.4K | 13.91M | +1% | +$3.94M | |
| 2025-12-23 | 2025-12-20 | ROIV | Pulik Richard | CFO | F - Tax | $22.41 | -2,129 | 386.1K | -0.5% | -$47.7K | |
| D | 2025-12-19 | 2025-12-17 | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | J - Other | $23.09 | -32.7K | 18.84M | -0.2% | -$754.6K |
| D | 2025-12-19 | 2025-12-17 | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | S - Sale+OE | $23.09 | -26.8K | 18.87M | -0.1% | -$619.5K |
| D | 2025-12-19 | 2025-12-17 | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | M - OptEx | $12.68 | +59.5K | 18.90M | +0.3% | +$754.6K |
| MI | 2025-12-18 | 2025-12-16+ | ROIV | QVT Financial LP | Dir by Deputization | S - Sale | $23.05 | -1.69M | 16.54M | -9% | -$39.07M |
| MI | 2025-12-18 | 2025-12-16+ | ROIV | Gold Daniel Allen | Dir | S - Sale | $23.05 | -1.69M | 16.70M | -9% | -$39.07M |
| MI | 2025-12-18 | 2025-12-16+ | ROIV | MANCHESTER KEITH S | Dir | S - Sale | $23.05 | -1.69M | 16.54M | -9% | -$39.07M |
| DM | 2025-12-17 | 2025-12-15 | ROIV | Gline Matthew | CEO, Dir | S - Sale+OE | $21.68 | -1.74M | 18.08M | -9% | -$37.72M |
| DM | 2025-12-17 | 2025-12-15 | ROIV | Gline Matthew | CEO, Dir | J - Other | $21.68 | -2.13M | 17.29M | -11% | -$46.19M |
| DM | 2025-12-17 | 2025-12-15 | ROIV | Gline Matthew | CEO, Dir | M - OptEx | $12.16 | +3.87M | 18.65M | +26% | +$47.06M |
| DM | 2025-12-15 | 2025-12-11+ | ROIV | Ramaswamy Vivek | 10% | M - OptEx | $12.68 | +7.37M | 34.49M | +27% | +$93.51M |
| DM | 2025-12-15 | 2025-12-11+ | ROIV | Ramaswamy Vivek | 10% | S - Sale+OE | $21.89 | -3.10M | 36.35M | -8% | -$67.94M |
| DM | 2025-12-15 | 2025-12-11+ | ROIV | Ramaswamy Vivek | 10% | J - Other | $21.89 | -4.27M | 33.65M | -11% | -$93.49M |
| DT | 2025-12-11 | 2025-12-09 | ROIV | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +200.0K | 1.70M | +13% | +$770.0K |
| DT | 2025-12-11 | 2025-12-09 | ROIV | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $20.85 | -200.0K | 1.50M | -12% | -$4.17M |
| 2025-11-24 | 2025-11-20 | ROIV | Pulik Richard | CFO | F - Tax | $20.27 | -1,235 | 388.3K | -0.3% | -$25.0K | |
| 2025-11-24 | 2025-11-20 | ROIV | Venker Eric | Pres, Immunovant CEO | F - Tax | $20.27 | -7,051 | 1.50M | -0.5% | -$142.9K | |
| MI | 2025-11-21 | 2025-11-19 | ROIV | Gold Daniel Allen | Dir | S - Sale | $20.23 | -1.30M | 18.50M | -7% | -$26.30M |
| MI | 2025-11-21 | 2025-11-19 | ROIV | MANCHESTER KEITH S | Dir | S - Sale | $20.23 | -1.30M | 18.05M | -7% | -$26.30M |
| MI | 2025-11-21 | 2025-11-19 | ROIV | QVT Financial LP | Dir by Deputization | S - Sale | $20.23 | -1.30M | 18.35M | -7% | -$26.30M |
| M | 2025-11-17 | 2025-11-13+ | ROIV | Ramaswamy Vivek | 10% | S - Sale | $20.46 | -1.85M | 34.19M | -5% | -$37.94M |
| DT | 2025-11-07 | 2025-11-07 | ROIV | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +200.0K | 1.70M | +13% | +$770.0K |
| DT | 2025-11-07 | 2025-11-07 | ROIV | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $20.22 | -200.0K | 1.50M | -12% | -$4.04M |
| 2025-10-22 | 2025-10-20 | ROIV | Oren Ilan | Dir | A - Grant | $0.00 | +1,507 | 118.7K | +1% | $0 | |
| 2025-10-22 | 2025-10-20 | ROIV | Oren Ilan | Dir | F - Tax | $17.74 | -281 | 118.4K | -0.2% | -$4,985 | |
| 2025-10-22 | 2025-10-20 | ROIV | Epperly Melissa B, | Dir | A - Grant | $0.00 | +1,056 | 56.9K | +2% | $0 | |
| 2025-10-22 | 2025-10-20 | ROIV | MOMTAZEE JAMES C | Dir | A - Grant | $0.00 | +789 | 108.7K | +0.7% | $0 | |
| 2025-10-22 | 2025-10-20 | ROIV | MOMTAZEE JAMES C | Dir | F - Tax | $17.74 | -158 | 108.5K | -0.1% | -$2,803 | |
| DMT | 2025-10-17 | 2025-10-15+ | ROIV | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $16.99 | -851.4K | 1.50M | -36% | -$14.47M |
| DMT | 2025-10-17 | 2025-10-15+ | ROIV | Venker Eric | Pres, Immunovant CEO | M - OptEx | $15.85 | +851.4K | 1.82M | +88% | +$13.49M |
| DMT | 2025-10-14 | 2025-10-09+ | ROIV | Venker Eric | Pres, Immunovant CEO | M - OptEx | $15.85 | +125.7K | 1.53M | +9% | +$1.99M |
| DMT | 2025-10-14 | 2025-10-09+ | ROIV | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $16.29 | -125.7K | 1.50M | -8% | -$2.05M |
| DMT | 2025-10-08 | 2025-10-06+ | ROIV | Venker Eric | Pres, Immunovant CEO | M - OptEx | $8.95 | +665.2K | 1.68M | +66% | +$5.96M |
| DMT | 2025-10-08 | 2025-10-06+ | ROIV | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $16.21 | -665.2K | 1.50M | -31% | -$10.78M |
| 2025-09-30 | 2025-09-28 | ROIV | Pulik Richard | CFO | F - Tax | $15.17 | -2,341 | 389.5K | -0.6% | -$35.5K | |
| 2025-09-23 | 2025-09-20 | ROIV | Pulik Richard | CFO | F - Tax | $15.04 | -2,129 | 391.8K | -0.5% | -$32.0K | |
| DMT | 2025-09-23 | 2025-09-19+ | ROIV | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +1.56M | 2.53M | +161% | +$6.02M |
| DMT | 2025-09-23 | 2025-09-19+ | ROIV | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $14.92 | -1.71M | 2.12M | -45% | -$25.52M |
| 2025-09-18 | 2025-09-18 | ROIV | Gline Matthew | CEO, Dir | P - Purchase | $15.07 | +3,315 | 17.29M | +0.0% | +$50.0K | |
| D | 2025-09-12 | 2025-09-10 | ROIV | Epperly Melissa B, | Dir | J - Other | $13.77 | -1,661 | 55.8K | -3% | -$22.9K |
| D | 2025-09-12 | 2025-09-10 | ROIV | Epperly Melissa B, | Dir | A - Grant | $0.00 | +14.5K | 57.5K | +34% | $0 |
| D | 2025-09-12 | 2025-09-10 | ROIV | Fitzgerald Meghan | Dir | A - Grant | $0.00 | +14.5K | 43.9K | +49% | $0 |
| D | 2025-09-12 | 2025-09-10 | ROIV | Fitzgerald Meghan | Dir | J - Other | $13.77 | -937 | 43.0K | -2% | -$12.9K |
| D | 2025-09-12 | 2025-09-10 | ROIV | Gold Daniel Allen | Dir | A - Grant | $0.00 | +14.5K | 8.97M | +0.2% | $0 |
| D | 2025-09-12 | 2025-09-10 | ROIV | Gold Daniel Allen | Dir | J - Other | $13.77 | -5,270 | 8.97M | -0.1% | -$72.6K |
| D | 2025-09-12 | 2025-09-10 | ROIV | MOMTAZEE JAMES C | Dir | J - Other | $13.77 | -3,282 | 107.9K | -3% | -$45.2K |
| D | 2025-09-12 | 2025-09-10 | ROIV | MOMTAZEE JAMES C | Dir | A - Grant | $0.00 | +14.5K | 111.2K | +15% | $0 |
| D | 2025-09-12 | 2025-09-10 | ROIV | MANCHESTER KEITH S | Dir | A - Grant | $0.00 | +14.5K | 1.95M | +0.8% | $0 |
| D | 2025-09-12 | 2025-09-10 | ROIV | Oren Ilan | Dir | J - Other | $13.77 | -2,043 | 117.2K | -2% | -$28.1K |
| D | 2025-09-12 | 2025-09-10 | ROIV | Oren Ilan | Dir | A - Grant | $0.00 | +14.5K | 119.2K | +14% | $0 |
| M | 2025-09-05 | 2025-09-03+ | ROIV | Ramaswamy Vivek | 10% | S - Sale | $12.65 | -1.78M | 36.09M | -5% | -$22.46M |
| 2025-09-02 | 2025-08-28 | ROIV | Pulik Richard | CFO | F - Tax | $11.94 | -2,340 | 394.0K | -0.6% | -$27.9K | |
| DT | 2025-08-22 | 2025-08-20 | ROIV | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +100.0K | 1.75M | +6% | +$385.0K |
| DT | 2025-08-22 | 2025-08-20 | ROIV | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $11.72 | -100.0K | 1.65M | -6% | -$1.17M |
| DT | 2025-08-22 | 2025-08-20 | ROIV | Venker Eric | Pres, Immunovant CEO | F - Tax | $11.72 | -7,051 | 1.65M | -0.4% | -$82.6K |
| 2025-08-22 | 2025-08-20 | ROIV | Pulik Richard | CFO | F - Tax | $11.72 | -1,235 | 396.3K | -0.3% | -$14.5K | |
| 2025-08-01 | 2025-07-30 | ROIV | Venker Eric | Pres, Immunovant CEO | A - Grant | $0.00 | +198.4K | 1.66M | +14% | $0 | |
| M | 2025-08-01 | 2025-07-30 | ROIV | Torti Frank | Pres, Vant COB | A - Grant | $0.00 | +13.74M | 13.74M | New | $0 |
| 2025-07-30 | 2025-07-28 | ROIV | Pulik Richard | CFO | F - Tax | $11.35 | -1,919 | 397.6K | -0.5% | -$21.8K | |
| DT | 2025-07-23 | 2025-07-21 | ROIV | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $11.52 | -100.0K | 1.46M | -6% | -$1.15M |
| DT | 2025-07-23 | 2025-07-21 | ROIV | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +100.0K | 1.56M | +7% | +$385.0K |
| 2025-07-21 | 2025-04-17 | ROIV | Oren Ilan | Dir | A - Grant | $0.00 | +2,296 | 104.8K | +2% | $0 | |
| 2025-07-21 | 2025-04-17 | ROIV | Oren Ilan | Dir | F - Tax | $11.65 | -115 | 104.7K | -0.1% | -$1,340 | |
| 2025-07-21 | 2025-07-17 | ROIV | Epperly Melissa B, | Dir | A - Grant | $0.00 | +1,609 | 43.0K | +4% | $0 | |
| 2025-07-21 | 2025-07-17 | ROIV | MOMTAZEE JAMES C | Dir | A - Grant | $0.00 | +1,201 | 96.9K | +1% | $0 | |
| 2025-07-21 | 2025-07-17 | ROIV | MOMTAZEE JAMES C | Dir | F - Tax | $11.65 | -241 | 96.7K | -0.2% | -$2,808 | |
| 2025-07-01 | 2025-06-28 | ROIV | Pulik Richard | CFO | F - Tax | $11.39 | -1,653 | 399.5K | -0.4% | -$18.8K | |
| MI | 2025-06-27 | 2025-06-25 | ROIV | Gold Daniel Allen | Dir | J - Other | $0.00 | -36.76M | 8.44M | -81% | $0 |
| MI | 2025-06-27 | 2025-06-25 | ROIV | MANCHESTER KEITH S | Dir | J - Other | $0.00 | -17.39M | 1.59M | -92% | $0 |
| MI | 2025-06-27 | 2025-06-25 | ROIV | QVT Financial LP | Dir by Deputization | J - Other | $0.00 | -36.76M | 8.44M | -81% | $0 |
| 2025-06-24 | 2025-06-20 | ROIV | Pulik Richard | CFO | F - Tax | $11.45 | -1,503 | 399.1K | -0.4% | -$17.2K | |
| DT | 2025-06-24 | 2025-06-20 | ROIV | Venker Eric | Pres, COO | M - OptEx | $3.85 | +100.0K | 1.56M | +7% | +$385.0K |
| DT | 2025-06-24 | 2025-06-20 | ROIV | Venker Eric | Pres, COO | S - Sale+OE | $11.45 | -100.0K | 1.46M | -6% | -$1.15M |
| M | 2025-06-23 | 2025-06-18+ | ROIV | Ramaswamy Vivek | 10% | S - Sale | $11.46 | -1.14M | 37.86M | -3% | -$13.08M |
| M | 2025-06-06 | 2025-06-04+ | ROIV | Ramaswamy Vivek | 10% | S - Sale | $11.30 | -748.2K | 38.43M | -2% | -$8.45M |
| DM | 2025-06-04 | 2025-06-02+ | ROIV | Venker Eric | Pres, COO | S - Sale+OE | $11.15 | -1.00M | 1.24M | -45% | -$11.15M |
| DM | 2025-06-04 | 2025-06-02+ | ROIV | Venker Eric | Pres, COO | M - OptEx | $3.85 | +1.39M | 1.68M | +474% | +$5.33M |
| 2025-05-30 | 2025-05-28 | ROIV | Pulik Richard | CFO | F - Tax | $10.62 | -1,653 | 400.6K | -0.4% | -$17.6K | |
| 2025-05-22 | 2025-05-20 | ROIV | Pulik Richard | CFO | F - Tax | $11.04 | -3,487 | 402.2K | -0.9% | -$38.5K | |
| DT | 2025-05-22 | 2025-05-20 | ROIV | Venker Eric | Pres, COO | M - OptEx | $3.85 | +100.0K | 1.18M | +9% | +$385.0K |
| DT | 2025-05-22 | 2025-05-20 | ROIV | Venker Eric | Pres, COO | S - Sale+OE | $10.95 | -100.0K | 1.08M | -8% | -$1.09M |
| DT | 2025-05-22 | 2025-05-20 | ROIV | Venker Eric | Pres, COO | F - Tax | $11.04 | -39.1K | 1.08M | -4% | -$432.2K |
| 2025-05-22 | 2025-05-20 | ROIV | Gline Matthew | CEO, Dir | F - Tax | $11.04 | -10.9K | 17.28M | -0.1% | -$120.8K | |
| M | 2025-05-08 | 2025-05-06+ | ROIV | Ramaswamy Vivek | 10% | S - Sale | $11.27 | -899.0K | 39.80M | -2% | -$10.13M |
| 2025-04-30 | 2025-04-28 | ROIV | Pulik Richard | CFO | F - Tax | $11.19 | -1,653 | 405.7K | -0.4% | -$18.5K | |
| D | 2025-04-23 | 2025-04-21 | ROIV | Pulik Richard | CFO | A - Grant | $0.00 | +141.5K | 407.4K | +53% | $0 |
| 2025-04-22 | 2025-04-20 | ROIV | Gline Matthew | CEO, Dir | F - Tax | $10.15 | -10.9K | 17.29M | -0.1% | -$111.1K | |
| DT | 2025-04-22 | 2025-04-21 | ROIV | Venker Eric | Pres, COO | S - Sale+OE | $10.22 | -100.0K | 1.12M | -8% | -$1.02M |
| DT | 2025-04-22 | 2025-04-21 | ROIV | Venker Eric | Pres, COO | M - OptEx | $3.85 | +100.0K | 1.22M | +9% | +$385.0K |
| DT | 2025-04-22 | 2025-04-20 | ROIV | Venker Eric | Pres, COO | F - Tax | $10.15 | -10.9K | 1.12M | -1.0% | -$111.1K |
| 2025-04-21 | 2025-04-17 | ROIV | Oren Ilan | Dir | A - Grant | $0.00 | +2,635 | 102.6K | +3% | $0 | |
| 2025-04-21 | 2025-04-17 | ROIV | Oren Ilan | Dir | F - Tax | $10.15 | -64 | 102.5K | -0.1% | -$649.60 | |
| 2025-04-21 | 2025-04-17 | ROIV | Epperly Melissa B, | Dir | A - Grant | $0.00 | +1,847 | 41.4K | +5% | $0 | |
| 2025-04-21 | 2025-04-17 | ROIV | MOMTAZEE JAMES C | Dir | A - Grant | $0.00 | +1,379 | 96.0K | +1% | $0 | |
| 2025-04-21 | 2025-04-17 | ROIV | MOMTAZEE JAMES C | Dir | F - Tax | $10.15 | -276 | 95.7K | -0.3% | -$2,801 | |
| 2025-04-01 | 2025-03-28 | ROIV | Pulik Richard | CFO | F - Tax | $10.38 | -1,653 | 265.9K | -0.6% | -$17.2K |
Purchase Sale Sale after option exercise All abbreviations